Pediatric hepatitis C infection: To treat or not to treat...what's the best for the child?

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 9, 2011, Pages 1057-1067

  Serranti, D ^a   Buonsenso, D ^a   Ceccarelli, M ^a   Gargiullo, L ^a   Ranno, O ^a   Valentini, Piero ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Early treatment; Efficacy; HCV; Mother to child; PEG IFN

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADVERSE OUTCOME; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENE; VIRUS TRANSMISSION;

AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERONS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80054858340     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. SHEPARD CW, FINELLI L, ALTER MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. SLOWIK MK, JHAVERI R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16: 296-305.
3. ALTER MJ, KRUSZON-MORAN D, NAINAN OV, MCQUILLAN GM, GAO F, MOYER LA, KASLOW RA, MARGOLIS HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
4. YEUNG LT, KING SM, ROBERTS EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-229.
5. GESSONI G, MANONI F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med 1993; 2: 79-82.
6. NGATCHU T, STROFFOUNI T, RAPICETTA M, CHIONNE P, LANTUM D, CHIARAMONTE M. Seroprevalence of antiHCV in an urban child population: a pilot survey in a developing area, Cameroon. J Trop Med Hyg 1992; 95: 57-61.
7. TANAKA E, KIYOSAWA K, SODEYAMA T, HAYATA T, OHIKE Y, NAKANO Y, YOSHIZAWA K, FURUTA S, WATANABE Y, WATANABE J, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg 1992; 46: 460-464.
8. RESTI M, AZZARI C, MANNELLI F, MORIONDO M, NOVEMBRE E, DE MARTINO M, VIERUCCI A. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Br Med J 1998 15; 317(7156): 437-441.
9. EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORK. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001; 108: 371-377.
10. ROBERTS EA, YEUNG L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36(5 Suppl 1): S106-113.
11. ZANETTI AR, TANZI E, PACCAGNINI S, PRINCIPI N, PIZZOCOLO G, CACCAMO ML, D'AMICO E, CAMBIÈ G, VECCHI L. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345(8945): 289-291.
12. AZZARI C, RESTI M, MORIONDO M, FERRARI R, LIONETTI P, VIERUCCI A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96: 2045-2048.
13. MAST EE, HWANG LY, SETO DS, NOLTE FS, NAINAN OV, WURTZEL H, ALTER MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880-1889.
14. AZZARI C, MORIONDO M, INDOLFI G, BETTI L, GAMBINERI E, DE MARTINO M, RESTI M. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80: 65-71.
15. PEMBREY L, NEWELL ML, TOVO PA; EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORKPEDIATR INFECT DIS J. Age-related lymphocyte and neutrophil levels in children of hepatitis C-infected women. Pediatr Infect Dis J 2008; 27: 800-807.
16. STEININGER C, KUNDI M, JATZKO G, KISS H, LISCHKA A, HOLZMANN H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003; 187: 345-351.
17. DUNN DT, GIBB DM, HEALY M, GOODALL RL, BUTLER K, CAFFERKEY M, NEAVE P. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. Pediatr Infect Dis J 2001; 20: 715-716.
18. PEMBREY L, NEWELL ML, TOVO PA; EPHN COLLABORATORS. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol 2005; 43: 515-525.
19. POLYWKA S, PEMBREY L, TOVO PA, NEWELL ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78: 305-310.
20. RESTI M, BORTOLOTTI F, VAJRO P, MAGGIORE G; COMMITTEE OF HEPATOLOGY OF THE ITALIAN SOCIETY OF PEDIATRIC GASTROENTEROLOGY AND HEPATOLOGY. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis 2003; 35: 453-457.
21. RESTI M, JARA P, HIERRO L, AZZARI C, GIACCHINO R, ZUIN G, ZANCAN L, PEDDITZI S, BORTOLOTTI F. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70: 373-377.
22. EUROPEAN PAEDIATRIC HEPATITIS C VIRUS NETWORK. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 45-51.
23. IORIO R, GIANNATTASIO A, SEPE A, TERRACCIANO LM, VECCHIONE R, VEGNENTE A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41: 1431-1437.
24. GUIDO M, BORTOLOTTI F, LEANDRO G, JARA P, HIERRO L, LARRAURI J, BARBERA C, GIACCHINO R, ZANCAN L, BALLI F, CRIVELLARO C, CRISTINA E, PUCCI A, RUGGE M. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003; 98: 660-663.
25. GOODMAN ZD, MAKHLOUF HR, LIU L, BAUSTRERI W, GONZALEZ-PERALTA RP, HABER B, JONAS MM, MOHAN P, MOLLESTON JP, MURRAY KF, NARKEWICZ MR, ROSENTHAL P, SMITH LJ, ROBUCK PR, SCHWARZ KB. Pathology of chronic hepatitis C in children: liver biopsy findings in the PedsC Trial. Hepatology 2008; 47: 836-843.
26. GONZÁLEZ-PERALTA RP, LANGHAM MR JR, ANDRES JM, MOHAN P, COLOMBANI PM, ALFORD MK, SCHWARZ KB. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635.
27. RODRIGUE JR, BALISTRERI W, HABER B, JONAS MM, MOHAN P, MOLLESTON JP, MURRAY KF, NARKEWICZ MR, ROSENTHAL P, SMITH LJ, SCHWARZ KB, ROBUCK P, BARTON B, GONZÁLEZ-PERALTA RP. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-347.
28. JACOBSON KR, MURRAY K, ZELLOS A, SCHWARZ KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-58.
29. FRIED MW, PETER J, HOOTS K, GAGLIO PJ, TALBUT D, DAVIS PC, KEY NS, WHITE GC, LINDBLAD L, RICKLES FR, ABSHIRE TC. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36(4 Pt 1): 967-972.
30. MCHUTCHISON JG, LAWITZ EJ, SHIFFMAN ML, MUIR AJ, GALLER GW, MCCONE J, NYBERG LM, LEE WM, GHAUB RH, SCHIFF ER, GALATI JS, BACON BR, DAVIS MN, MUKHOPADHYAY P, KOURY K, NOVIELLO S, PEDICONE LD, BRASS CA, ALBRECHT JK, SULKOWSKI MS; IDEAL STUDY TEAM. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
31. GHAFFAR TY, EL NAGHY S, EL SEBAIE H, EL MONAIERY M, GHAFFAR AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009; 76: 895-898.
32. TAJIRI H, INUI A, KIYOHARA Y, SUZUKI M, KAGIMOTO S, ETANI Y, SHIMIZU T, FUJISAWA T. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-1260.
33. SOKAL EM, BOURGOIS A, STÉPHENNE X, SILVEIRA T, PORTA G, GARDOVSKA D, FISCHLER B, KELLY D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-831.
34. WIRTH S, RIBES-KONINCKX C, CALZADO MA, BORTOLOTTI F, ZANCAN L, JARA P, SHELTON M, KERKAR N, GALOPPO M, PEDREIRA A, RODRIGUEZ-BAEZ N, CIOCCA M, LACHAUX A, LACAILLE F, LANG T, KULLMER U, HUBER WD, GONZALEZ T, POLLACK H, ALONSO E, BROUE P, RAMAKRISHNA J, NEIGUT D, VALLE-SEGARRA AD, HUNTER B, GOODMAN Z, XU CR, ZHENG H, NOVIELLO S, SNIUKIENE V, BRASS C, ALBRECHT JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507.
35. JARA P, HIERRO L, DE LA VEGA A, DÍAZ C, CAMARENA C, FRAUCA E, MIÑOS-BARTOLO G, DÍEZ-DORADO R, DE GUEVARA CL, LARRAURI J, RUEDA M. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-148.
36. BAKER RD, DEE D, BAKER SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007; 41: 111-114.
37. WIRTH S, PIEPER-BOUSTANI H, LANG T, BALLAUFF A, KULLMER U, GERNER P, WINTERMEYER P, JENKE A. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018.
38. SCHWARZ KB, GONZALEZ-PERALTA RP, MURRAY KF, MOLLESTON JP, HABER BA, JONAS MM, ROSENTHAL P, MOHAN P, BALISTRERI WF, NARKEWICZ MR, SMITH L, LOBRITTO SJ, ROSSI S, VALSAMAKIS A, GOODMAN Z, ROBUCK PR, BARTON BA; PEDS-C CLINICAL RESEARCH NETWORK. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents chronic hepatitis C. Gastroenterology 2010; Oct 28. [Epub ahead of print].
39. HADZIYANNIS SJ, SETTE H JR, MORGAN TR, BALAN V, DIAGO M, MARCEUJN P, RAMADORI G, BODENHEIMER H JR, BERNSTEIN D, RIZZETTO M, ZEUZEM S, POCKROS PJ, LIN A, ACKRILL AM; PEGASYS INTERNATIONAL STUDY GROUP. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
40. GONZÁLEZ-PERALTA Rp. Treatment of chronic hepatitis C in children. Pediatr Transplant 2004; 8: 639-643.
41. JHAVERI R, GRANT W, KAUF TL, MCHUTCHISON J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148: 353-358.
42. KARNSAKUL W, ALFORD MK, SCHWARZ KB. Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag 2009; 5: 651-660.
43. COREY KE, MENDEZ-NAVARRO J, GOROSPE EC, ZHENG H, CHUNG RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17: 201-207.